Mersana Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events, sending shares of the company tumbling.
Struggling Swedish real estate group SBB is broadening a strategic review to include the options of a potential sale of the whole company or some of its business segments, it said on Monday, sending its shares up more than 9%.